KS-133 TFA
Based on 1 Customer Validation
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.95%
- Formule: C77H112F3N15O19S2
- Masse moléculaire:1672.93
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PACAP Receptor
More
Activité biologique
KS-133 (1-10 μM, 3 d) can transform the polarity of macrophages from the pro-tumor M2 type to the anti-tumor M1 type by inhibiting VIPR2[2].
KS-133 can be prepared as nanoparticles, which can cross the blood-brain barrier and enhance its anti-tumor and neuroprotective activities[2][3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 cells
-
Concentration:1, 3, 10 μM
-
Incubation Time:3 d
-
Result:Significantly upregulated the mRNA expression of M1-type markers iNOS and CXCL10.
Significantly downregulated the mRNA expression of the M2-type marker Mrc-1.
KS-133 (30 μg/mouse, s.c., once daily for 3 weeks) has anti-tumor activity in mice against the CT26 colorectal cancer model, and shows a synergistic effect when combined with anti-PD-1 antibodies[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Schizophrenic-like phenotype model established in ICR neonatal mice at P12 (7-10 g body weight)[1]
-
Dosage:1 nmol/g
-
Administration:Subcutaneous injection (s.c.), once daily for 14 days
-
Result:Significantly improved the cognitive function of the model mice, restoring their discrimination index to a level close to normal.
Significantly reversed the abnormal neural morphology, restoring the normal size of neurons and the complexity of dendrites.
-
Animal Model:CT26 colorectal cancer model established in female BALB/cCrSlc mice at P12 (6 weeks)[2]
-
Dosage:30 μg/mouse with or without 200 μg/mouse anti-PD-1 antibody
-
Administration:Subcutaneous injection (s.c.), once daily for 3 weeks
-
Result:Had anti-tumor activity in vivo against the CT26 colorectal cancer model, and showed a synergistic effect when combined with anti-PD-1 antibodies.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1672.93
-
Formule C77H112F3N15O19S2
-
Color White to off-white
-
Sequence
Ac-Cys-Pro-Pro-Tyr-Leu-Pro-cyclo(Lys-Tyr-Leu-Cys-Asp)-Leu-Ile-NH2 (disulfide bridge:Cys1-Cys10)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
DMSO : 100 mg/mL (59.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (1.49 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (290 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kotaro Sakamoto, et al. Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders. Front Pharmacol. 2021 Nov 4:12:751587. [Content Brief]
[2]. Sakamoto K, et al. The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody. PLoS One. 2023 Jul 5;18(7):e0286651. [Content Brief]
[3]. Sakamoto K, et al. Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating Schizophrenia. JACS Au. 2024 Jun 20;4(8):2811-2817. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.5978 mL | 2.9888 mL | 5.9775 mL | 14.9438 mL |
| 5 mM | 0.1196 mL | 0.5978 mL | 1.1955 mL | 2.9888 mL | |
| 10 mM | 0.0598 mL | 0.2989 mL | 0.5978 mL | 1.4944 mL | |
| 15 mM | 0.0399 mL | 0.1993 mL | 0.3985 mL | 0.9963 mL | |
| 20 mM | 0.0299 mL | 0.1494 mL | 0.2989 mL | 0.7472 mL | |
| 25 mM | 0.0239 mL | 0.1196 mL | 0.2391 mL | 0.5978 mL | |
| 30 mM | 0.0199 mL | 0.0996 mL | 0.1993 mL | 0.4981 mL | |
| 40 mM | 0.0149 mL | 0.0747 mL | 0.1494 mL | 0.3736 mL | |
| 50 mM | 0.0120 mL | 0.0598 mL | 0.1196 mL | 0.2989 mL |
KS-133 TFA Related Classifications
HY-P6292A Related Classifications
Powered by Bioz